Table 2. Efficacy of dovitinib treatment for hemangioblastomas in Von Hippel Lindau patients.
| Patient | Best response | Discontinuation reason | Cycles completed |
|---|---|---|---|
| A | SD | Non-compliant/AE | 12 |
| B | SD | AE | 2 |
| C | SD | Progression/AE | 6 |
| D | SD | AE | 4 |
| E | SD | AE | 2 |
| F | SD | Completed study | 8 |
Abbreviations: SD = stable disease; AE = adverse event.